The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model

Archive ouverte

Cochin, Maxime | Luciani, Léa | Touret, Franck | Driouich, Jean-Sélim | Petit, Paul-Rémi | Moureau, Grégory | Baronti, Cécile | Laprie, Caroline | Thirion, Laurence | Maes, Piet | Boudewijns, Robbert | Neyts, Johan | de Lamballerie, Xavier | Nougairède, Antoine

Edité par CCSD ; Nature Publishing Group -

International audience. Late 2020, SARS-CoV-2 Alpha variant emerged in United Kingdom and gradually replaced G614 strains initially involved in the global spread of the pandemic. In this study, we use a Syrian hamster model to compare a clinical strain of Alpha variant with an ancestral G614 strain. The Alpha variant succeed to infect animals and to induce a pathology that mimics COVID-19. However, both strains replicate to almost the same level and induced a comparable disease and immune response. A slight fitness advantage is noted for the G614 strain during competition and transmission experiments. These data do not corroborate the epidemiological situation observed during the first half of 2021 in humans nor reports that showed a more rapid replication of Alpha variant in human reconstituted bronchial epithelium. This study highlights the need to combine data from different laboratories using various animal models to decipher the biological properties of newly emerging SARS-CoV-2 variants. © 2022. The Author(s).

Suggestions

Du même auteur

Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages

Archive ouverte | Driouich, Jean-Sélim | CCSD

International audience. Therapeutic monoclonal antibodies have been successful in protecting vulnerable populations against SARS-CoV-2. However, their effectiveness has been hampered by the emergence of new variants...

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Archive ouverte | Driouich, Jean-Sélim | CCSD

International audience. Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a Syrian h...

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Archive ouverte | Driouich, Jean-Sélim | CCSD

International audience. BACKGROUND : To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started, including those involving an oral treatment by nitazoxanide, despite no or limite...

Chargement des enrichissements...